Xenetic Biosciences Q2 net loss $1.1M; expands DNase platform with VolitionRx SOW

Xenetic Biosciences, Inc.

2023-Q2 EPS reported -$1.25 revenue$1,256,849

Net loss of ~$1.1M for Q2 2023; R&D expenses fell 56.5% to ~$0.9M vs $2.1M in Q2 2022.
Royalty payments from Takeda sublicense were ~$0.7M in Q2 2023, up 56.2% from prior year.
Cash position of ~$10.7M at quarter end; no outstanding debt.
Executed first Collaborator SOW with VolitionRx and CLS for NETs-targeted CAR T cell therapies in solid cancers.
Advancing DNase-based oncology program towards Phase 1 study for pancreatic carcinoma and other solid tumors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xenetic Biosciences, Inc. reported financial results for second quarter of 2023.

Period: second quarter of 2023
Result: reported results

Exact text from the filing

On August 11, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended June 30, 2023 and providing a corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and hereby incorporated in this Item 2.02 by reference.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-005538

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.